N
InspireMD, Inc.
NSPRCIK 0001433607NasdaqNon-AcceleratedSmaller ReportingSurgical & Medical Instruments & ApparatusDelawareFY ends Dec 31
Period
FY 2025
Revenue
$8.98M
Net Income
$-48.79M
Total Assets
$69.40M
Equity
$55.20M
Shares Out
46.80M
Op. Cash Flow
$-35.10M
Business
InspireMD, Inc. is a medical device company that develops and commercializes mesh-covered stent systems and related neuroprotection devices for treatment of carotid and other vascular disease. Its main products include the MicroNet mesh platform, the CGuard embolic prevention stent system and the next-generation CGuard Prime stent, together with the SwitchGuard neuroprotection system and associated delivery systems. Business activities encompass product development, regulatory clinical trials, manufacturing and commercialization. The company sells through distributor networks across Europe, Latin America and Asia while building a direct U.S. commercial organization and conducting FDA trials.
Summary from filing dated 2025-03-12
Financials
Consolidated Statement of Income
Year Ended · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| REVENUES | 9 | 7 | 6 | 5 | 4 | |
| COST OF REVENUES | 6 | 6 | 4 | 4 | 4 | |
| GROSS PROFIT | 3 | 2 | 2 | 1 | 754,000 | |
| Research and development | 15 | 14 | 8 | 8 | 5 | |
| Selling and marketing | 17 | 6 | 4 | 4 | 3 | |
| General and administrative | 21 | 15 | 11 | 8 | 7 | |
| Total operating expenses | 52 | 35 | 23 | 20 | 15 | |
| LOSS FROM OPERATIONS | −50 | −34 | −21 | −19 | −15 | |
| FINANCIAL INCOME, net: | 891,000 | 2 | 1 | 250,000 | −157,000 | |
| LOSS BEFORE TAX EXPENSES | −49 | −32 | −20 | −18 | −15 | |
| TAX EXPENSES | 63,000 | 59,000 | 65,000 | 28,000 | 45,000 | |
| NET LOSS | −49 | −32 | −20 | −18 | −15 | |
| NET LOSS PER SHARE - basic | −0.76 | −0.76 | −0.82 | −2.35 | −2.03 | |
| NET LOSS PER SHARE - diluted | −0.76 | −0.76 | −0.82 | −2.35 | — | |
| WEIGHTED AVERAGE NUMBER OF COMMON STOCK USED IN COMPUTING NET LOSS PER SHARE - basic | 64 | 42 | 24 | 8 | 7 | |
| WEIGHTED AVERAGE NUMBER OF COMMON STOCK USED IN COMPUTING NET LOSS PER SHARE - diluted | 64 | 42 | 24 | 8 | — |
Consolidated Balance Sheet
As of · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2025 2025-05-31 | FY 2024 2024-12-31 | FY 2024 2024-10-31 | FY 2023 2023-12-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 9 | — | 19 | — | 10 | |
| Marketable securities | 45 | — | 16 | — | 29 | |
| Trade, net | 2 | — | 2 | — | 2 | |
| Other | 400,000 | — | 682,000 | — | 648,000 | |
| Prepaid expenses | 1 | — | 1 | — | 578,000 | |
| Inventory | 3 | — | 3 | — | 2 | |
| TOTAL CURRENT ASSETS | 61 | — | 41 | — | 44 | |
| Long term deposit | 442,000 | — | 426,000 | 422,000 | — | |
| Property, plant and equipment, net | 4 | — | 2 | — | 1 | |
| Operating lease right of use assets | 3 | 302,000 | 2 | — | 1 | |
| Fund in respect of employee rights upon retirement | 1 | — | 1 | — | 951,000 | |
| TOTAL NON-CURRENT ASSETS | 8 | — | 6 | — | 3 | |
| TOTAL ASSETS | 69 | — | 47 | — | 48 | |
| Trade | 1 | — | 1 | — | 939,000 | |
| Other | 9 | — | 6 | — | 5 | |
| TOTAL CURRENT LIABILITIES | 11 | — | 8 | — | 6 | |
| Operating lease liabilities net of current maturities | 2 | — | 2 | — | 1 | |
| Liability for employee rights upon retirement and others | 1 | — | 1 | — | 1 | |
| TOTAL LONG-TERM LIABILITIES | 3 | — | 3 | — | 2 | |
| TOTAL LIABILITIES | 14 | — | 11 | — | 8 | |
| COMMITMENTS AND CONTINGENT LIABILITIES | — | — | — | — | — | |
| Common stock, par value $0.0001 per share; 150,000,000 shares authorized at December 31, 2025 and 2024; 43,532,281 and 26,611,033 shares issued and outstanding at December 31, 2025 and 2024, respectively | 4,000 | — | 3,000 | — | 2,000 | |
| Preferred C shares, par value $0.0001 per share; 1,172,000 shares authorized at December 31, 2025 and 2024; 1,718 shares issued and outstanding at December 31, 2025 and 2024, respectively | — | — | — | — | — | |
| Additional paid-in capital | 357 | — | 290 | — | 261 | |
| Accumulated deficit | −302 | — | −254 | — | −222 | |
| Total equity | 55 | — | 36 | — | 40 | |
| Total liabilities and equity | 69 | — | 47 | — | 48 |
Consolidated Statement of Cash Flows
Year Ended · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Depreciation | 476,000 | 280,000 | 232,000 | 188,000 | — | |
| Gain from sale of property, plant and equipment | −14,000 | — | −6,000 | — | −1,000 | |
| Change in fair value of marketable securities, net of interest received | −359,000 | −894,000 | −739,000 | — | — | |
| Change in liability for employees rights upon retirement | 20,000 | 163,000 | 89,000 | −57,000 | — | |
| Other financial income | −133,000 | −51,000 | 58,000 | 131,000 | 8,000 | |
| Change in operating right of use asset and operating leasing liability | 554,000 | −144,000 | 62,000 | −60,000 | −14,000 | |
| Share-based compensation expenses | 12 | 10 | 4 | 2 | 2 | |
| Gain on amounts funded in respect of employee rights upon retirement, net | −299,000 | −91,000 | −16,000 | — | — | |
| Increase in prepaid expenses | −236,000 | −482,000 | 77,000 | 7,000 | −188,000 | |
| Decrease (increase) in trade receivables | −596,000 | 232,000 | −770,000 | 190,000 | −748,000 | |
| Decrease (increase) in other receivables | 282,000 | −34,000 | −435,000 | −48,000 | −19,000 | |
| Increase in inventory | −826,000 | −464,000 | −485,000 | −478,000 | 272,000 | |
| Increase in trade payables | 1,000 | 315,000 | 280,000 | −234,000 | 657,000 | |
| Increase in other payables | 2 | 1 | 532,000 | 958,000 | −35,000 | |
| Net cash used in operating activities | −35 | −22 | −16 | −16 | −13 | |
| Purchase of property, plant and equipment | −2 | −1 | −381,000 | −473,000 | −344,000 | |
| Proceeds from sale of property, plant and equipment | 15,000 | — | 12,000 | — | — | |
| Investment in long-term deposit | — | −426,000 | — | — | — | |
| Investments in marketable securities | −57 | −14 | −35 | — | — | |
| Proceeds from matured marketable securities | 28 | 29 | 6 | — | — | |
| Amounts funded in respect of employee rights upon retirement | −91,000 | −87,000 | −79,000 | −86,000 | −113,000 | |
| Amounts withdrawn in respect of employee rights upon retirement | 370,000 | — | — | — | — | |
| Net cash provided by (used in) investing activities | −31 | 13 | −16 | 8 | −22 | |
| Proceeds from exercise of warrants, net of $1,000 issuance costs | 17 | 17 | — | — | — | |
| Proceeds from issuance of shares and pre-funded warrants, net of $ 3,148 and $81 issuance costs, respectively | 39 | 2 | — | — | — | |
| Net cash provided by financing activities | 56 | 18 | 38 | −140,000 | 35 | |
| EFFECT OF EXCHANGE RATE CHANGES ON CASH AND CASH EQUIVALENTS | 117,000 | 51,000 | −58,000 | −131,000 | −8,000 | |
| INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS | −10 | 9 | 5 | −7 | −641,000 | |
| Acquisition of right-of-use assets by means of lease liabilities | 994,000 | 1 | 419,000 | 835,000 | 91,000 | |
| Non-cash purchase of property and equipment | 28,000 | 189,000 | — | — | — |
Filings
Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro
Material Events
Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro
Insiders
Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro
Institutional Holders
Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro